December 5, 2019 We issued a bullish report on Aurinia Pharmaceuticals (NASDAQ: AUPH) on November 29, 2019 at $7.83 due to multiple bullish patterns

December 5, 2019

We issued a bullish report on Aurinia Pharmaceuticals (NASDAQ: AUPH) on November 29, 2019 at $7.83 due to multiple bullish patterns, a short squeeze underway and undervaluation.  AUPH is +147% in only a few trading days and the #1 gainer in the US pre-market this morning after announcing positive results for its lupus drug trial. Full valuation price target is $11.50. Take profits now.

Click for news https://yhoo.it/33RFGG3

Call Tom at (949)-230-7680 or email [email protected] 

REGISTER for alerts here: https://www.woprai.com

Follow us on Twitter: https://twitter.com/woprai

Click for report https://www.woprresearch.com/freereports3/auph20191129.pdf

Artificial Intelligence is a technology that uses machine intelligence and human like thinking ability to process historical and real-time data to make predictions, recommendations, and decisions. AI is not a single technology but a convergence of various technologies, statistical models, algorithms, and approaches. We have spent 23 years developing 11 categories of strategies that dynamically generate predictive research reports when multiple strategies line up at the same time in the same direction, with no conflicting strategies present.

Our founder and CEO has been on CNBC TV, BLOOMBERG TV, BNN TV, and published in PC Artificial Intelligence along with the Wall Street Journal, Dow Jones, CBS MarketWatch, Equities Magazine, SFO Magazine, Technical Analysis of Stocks and Commodities Magazine, Red Herring, MSNBC and has been an approved research analyst for Investor’s Business Daily. Mr. Ronk reached the Top 15 players (out of nearly 600,000 contestants) during CNBC’s Million Dollar Portfolio Challenge.

He was just awarded a 10 year GOLD MEDAL for beating all mutual fund managers over the past 10 years. This was all done USING THE TECHNOLOGY described in this email.